Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Elanco (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 p.m. EST).
A live audio webcast will be available in the Events and Presentations section of Elanco's investor website, and a replay will be available for a limited time after the event.
Positive
- None.
Negative
- None.
News Market Reaction – ELAN
In the Jan 6 session, ELAN gained 3.25%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 31 | USDA product approval | Positive | -0.6% | USDA approval of Befrena for canine allergic and atopic dermatitis. |
| Dec 18 | FDA conditional ok | Positive | +0.1% | FDA conditional approval for Credelio Quattro-CA1 to treat screwworm in dogs. |
| Dec 09 | Investor Day targets | Positive | -5.8% | Three‑year plan with growth, leverage and free cash flow targets to 2028. |
| Nov 26 | Board observer role | Positive | -0.2% | Elanco executive appointed board observer at Neurizon under license deal. |
| Nov 21 | FDA EUA granted | Positive | +4.8% | FDA Emergency Use Authorization for Credelio CAT to treat screwworm in cats. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive operational and regulatory news often saw mixed or negative next-day price reactions, with only some approvals aligning with positive moves.
This announcement follows a series of regulatory wins and strategic updates. In late 2025, Elanco gained USDA approval for Befrena, targeting the $1.3 billion U.S. canine dermatology market with a planned H1 2026 launch, and secured FDA conditional approval and an EUA for Credelio products addressing screwworm in dogs and cats. An Investor Day on Dec 9, 2025 set targets for mid‑single digit organic revenue growth and at least $1B free cash flow from 2026–2028. The current conference appearance fits into this ongoing investor communication effort.
Jargon Translator
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live audio webcast will be available in the "Events and Presentations" section of Elanco's investor website. A replay will be available for a limited time at the conclusion of the event.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
Investor Contact: Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com
Media Contact: Colleen Parr Dekker (317) 989-7011 colleen.dekker@elancoah.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/elanco-to-participate-in-the-44th-annual-jp-morgan-healthcare-conference-302653013.html
SOURCE Elanco Animal Health